Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Impact · against what's priced in

Myriad Genetics shows improving operational discipline and a path to profitability via cost-cutting and core franchise resilience. While revenue is slightly contracting and some segments face reimbursement headwinds, the positive EPS surprise suggests a fundamental shift in the company's financial profile.

MYGN+0.40

No priced-in read yet

In context

The company achieved positive adjusted EPS and stabilized gross margins at 70% through cost-cutting, though this is partially offset by a modest decline in overall revenue.

Read from the article alone

• earnings▲9%
• healthcare
• biotech
• MYGN
• cost cutting
• diagnostic testing
• genetics
• profitability

Top 1 mover · tap to explore